Bronstein, Gewirtz & Grossman, LLC said a securities class action has been filed against Replimune Group, Inc. and certain of its officers on behalf of investors who purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026. The complaint alleges the defendants violated federal securities laws by making false or misleading statements, or omitting material information, during that period. The allegations center on claims that Replimune did not address study design concerns previously communicated by the FDA (U.S. Food and Drug Administration) in connection with the BLA (Biologics License Application), and that it submitted data from an early, unplanned analysis of RP1-104 involving 40 patients, about 10% of the planned 400-patient enrollment. The complaint further claims those issues left RPL-001-16 and RP1-104 with deficiencies likely to cause the FDA to reject the BLA. Investors who suffered losses have until October 5, 2026 to ask the court to appoint them as lead plaintiff, though participation in any recovery does not require serving in that role.